MOUNTAIN VIEW, Calif. (AP) _ ChemoCentryx Inc. (CCXI) on Monday reported a loss of $29.9 million in its fourth quarter.
On a per-share basis, the Mountain View, California-based company said it had a loss of 43 cents.
The results fell short of Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 32 cents per share.
The biopharmaceutical company posted revenue of $4.4 million in the period, which also did not meet Street forecasts. Five analysts surveyed by Zacks expected $8.9 million.
For the year, the company reported that its loss narrowed to $55.4 million, or 84 cents per share. Revenue was reported as $64.9 million.
ChemoCentryx shares have climbed 10% since the beginning of the year. In the final minutes of trading on Monday, shares hit $68.40, an increase of 55% in the last 12 months.